A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
Inclusion Criteria
- Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:.
i) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or.
ii) M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or,.
iii) For participants without measurable disease in sPEP or uPEP: serum free light chain levels > 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light chain ratio.
Exclusion Criteria
Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
ABB, Buenos Aires F.D. C1199ABB, Argentina
Bogota, Cundinamarca 111151, Colombia
Hksar, 0, Hong Kong
Holon, Central District 5810001, Israel
Kitakyushu-shi, Fukuoka 806-8501, Japan
Higashiibaraki, Ibaraki 3113117, Japan
Shiwa-gun Yahaba-cho, Iwate 028-3695, Japan
Itabashiku, Tokyo 173-8610, Japan
Koto-ku, Tokyo 135-8550, Japan
L'Hospitalet Del Llobregat, Barcelona [Barcelona] 08908, Spain
Kaohsiung Niao Sung Dist, Kaohsiung 83301, Taiwan